Salvage treatment may be warranted after incomplete resection of rectal neuroendocrine tumors due to significant residual disease concerns. Incomplete resection rates: 73.1% for cold snare polypectomy; 29.8% for conventional EMR; 14.7% for endoscopic submucosal dissection. Residual tumor rate with salvage treatment is 25% (CI: 12%–40%). Individualized clinical decisions are crucial given the uncertainty in recurrence […]
Category: Sarcoma & rare tumors
New Immune Signatures in MEN1-Related Tumors
Identifying immune signatures could refine patient selection and surgical outcomes for those with MEN1-related neuroendocrine tumors. Analyzed 42 MEN1 patients with duodenopancreatic neuroendocrine tumors (DPNETs); 14 had liver metastasis. Identified 1,117 immunoglobulin-bound proteins; 435 antigens enriched in DPNET patients, with 130 higher in those with liver metastasis. Surgeons may consider these findings for better risk […]
Surgery improves outcomes for gastroenteropancreatic neuroendocrine tumors with liver metastasis.
Patients undergoing primary resection and metastasectomy for small-bowel neuroendocrine tumors (sbnets) had a mean disease-specific survival of 97 months, compared to 71.6 months for pancreatic neuroendocrine tumors (pnets). Surgical candidates who refused surgery had notably worse outcomes, with mean survivals of 73.5 months for sbnets and 56.5 months for pnets. Surgeons should prioritize surgical intervention […]
Predicting Recurrence in Lymph Node-Negative Pancreatic Tumors
A new risk score for lymph node-negative pancreatic neuroendocrine tumors helps identify patients at risk for recurrence and guides postoperative surveillance. Recurrence rate for lymph node-negative patients was 10.6%, occurring at a median of 32.4 months post-surgery. Risk factors included male sex (2.2x), tumor size ≥3 cm (2.64x), grade 2 or higher (3.70x), and lymphovascular […]
Outcomes for Retroperitoneal Sarcoma Patients Improve Significantly
Recent management of primary retroperitoneal sarcomas shows improved survival rates over time. 5-year overall survival increased from 61.7% (2002-2011) to 78.8% (2012-2021). Distant metastases rates decreased in the recent cohort (HR 1.50). These findings influence patient selection and highlight the need to adopt newer treatment strategies to enhance outcomes. 30-month post-recurrence survival rose dramatically from […]
Surgery First Improves Outcomes in Primary Intestinal Lymphoma
Surgery first significantly enhances survival and safety in primary intestinal lymphoma compared to chemotherapy first. 3-year and 5-year overall survival rates were higher in the surgery first group (p < 0.05). Patients under 60, with stage I-II disease and low international prognostic index (IPI) scores, saw even greater survival benefits (p < 0.05). You should […]
Perineural invasion worsens survival in resected pancreatic tumors
Patients with pancreatic neuroendocrine tumors (PNETs) and perineural invasion (PNI) face significantly worse outcomes post-surgery. PNI occurs in 24.4% of PNET patients and is linked to higher tumor grades and advanced disease stages. Patients with PNI have a median overall survival of 115.9 months, compared to no PNI patients whose median survival is not yet […]
Minimally Invasive Surgery Cuts Complications in Small Bowel Tumors
Minimally invasive surgery for small bowel neuroendocrine tumors shows significant benefits over open resection. MIS resulted in 54% lower odds of postoperative complications. Patients had shorter hospital stays (4 vs. 6 days) and fewer infections: skin/soft tissue (2.1% vs. 6.8%), urinary tract (0.5% vs. 2.4%), sepsis (0.2% vs. 1.2%). This approach enhances short-term outcomes and […]
Rising Rates of Gastric Neuroendocrine Tumors Change Surgical Care
Gastric neuroendocrine neoplasms are on the rise, necessitating improved prognostic tools for better surgical outcomes. Incidence increased 16-fold over 46 years, from 0.435 to 7.033 per 1,000,000 people. A newly developed nomogram showed superior predictive accuracy (c-index of 0.86) compared to the AJCC staging system. Understanding these risk factors—age, sex, tumor characteristics, and surgical intervention—can […]
Outcomes of Pancreatic Tumors Differ by Cancer Type
Surgeons need to know how outcomes differ between pancreatic neuroendocrine tumors (pnet) and ductal adenocarcinoma (pdac) after surgery. After pancreatoduodenectomy, ideal outcomes were lower for pnet (44.2%) vs. pdac (56.9%), with significantly higher severe complications (31.2% vs. 19.0%) and readmission rates (23.6% vs. 15.3%). In distal pancreatectomy, pnet had better ideal outcomes (60.1% vs. 57.1%), […]